Lonza Group AG

Lonza Group AG is a leading Swiss multinational specializing in contract development and manufacturing for the pharmaceutical, biotechnology, and nutrition industries. As one of the world’s largest CDMOs, Lonza partners with a diverse set of clients—from emerging biotechs to major pharmaceutical firms—to turn scientific discoveries into advanced, market-ready therapies. The company offers integrated services across the lifecycle of drug development, including biologics, small molecules, cell and gene therapies, and highly potent active pharmaceutical ingredients. Notably, Lonza is recognized as a global leader in the production of monoclonal antibodies, essential for treatments in fields like neurology and oncology. Headquartered in Basel, Switzerland, with more than 30 sites across five continents, Lonza’s operations combine cutting-edge science, robust manufacturing capabilities, and advanced technology platforms. The company’s commitment to operational excellence and innovation positions it as a vital enabler in bringing life-saving and life-enhancing medicines to patients worldwide, supporting pharmaceutical innovation, clinical research, and large-scale commercial manufacturing across the healthcare sector.